Celldex Therapeutics (CLDX) Competitors $24.30 +0.90 (+3.85%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$24.41 +0.11 (+0.45%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. ALKS, LGND, FOLD, BCRX, MNKD, INVA, NVAX, DVAX, OPK, and GERNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals MannKind Innoviva Novavax Dynavax Technologies OPKO Health Geron Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends. Which has more risk & volatility, ALKS or CLDX? Alkermes has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Do insiders & institutionals believe in ALKS or CLDX? 95.2% of Alkermes shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, ALKS or CLDX? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B2.95$367.07M$2.0813.39Celldex Therapeutics$5.79M278.70-$157.86M-$3.01-8.07 Does the media favor ALKS or CLDX? In the previous week, Alkermes had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 24 mentions for Alkermes and 13 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.14 beat Alkermes' score of 0.52 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALKS or CLDX? Alkermes presently has a consensus target price of $42.00, indicating a potential upside of 50.81%. Celldex Therapeutics has a consensus target price of $46.67, indicating a potential upside of 92.04%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is ALKS or CLDX more profitable? Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Celldex Therapeutics -3,446.88%-27.61%-26.20% SummaryAlkermes beats Celldex Therapeutics on 13 of the 17 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.52%P/E Ratio-8.0721.3475.6926.29Price / Sales278.70435.42518.33172.80Price / CashN/A45.5837.2059.76Price / Book2.1610.0511.516.41Net Income-$157.86M-$53.33M$3.28B$270.56M7 Day Performance2.92%1.39%1.45%3.13%1 Month Performance17.62%11.91%11.30%9.74%1 Year Performance-42.20%13.21%59.09%28.17% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.685 of 5 stars$24.30+3.8%$46.67+92.0%-42.5%$1.61B$5.79M-8.07150Positive NewsALKSAlkermes4.6573 of 5 stars$28.97+0.1%$41.08+41.8%+3.8%$4.78B$1.56B13.931,800News CoverageAnalyst ForecastOptions VolumeLGNDLigand Pharmaceuticals4.0595 of 5 stars$161.71+1.1%$165.17+2.1%+60.9%$3.17B$167.13M-40.4380Positive NewsShort Interest ↑FOLDAmicus Therapeutics4.1035 of 5 stars$7.59-0.8%$16.22+113.7%-31.5%$2.34B$528.29M-63.24480Positive NewsBCRXBioCryst Pharmaceuticals4.2498 of 5 stars$8.31-1.9%$16.70+101.0%+5.3%$1.74B$450.71M-46.16530Positive NewsMNKDMannKind4.4054 of 5 stars$4.59+2.2%$9.50+107.0%-9.7%$1.41B$285.50M41.73400Gap UpINVAInnoviva4.7347 of 5 stars$20.43+2.0%$42.75+109.3%+4.8%$1.29B$358.71M65.91100Positive NewsNVAXNovavax4.607 of 5 stars$7.47-1.5%$14.29+91.2%-37.7%$1.21B$682.16M3.281,990DVAXDynavax Technologies4.5907 of 5 stars$10.12-1.5%$24.33+140.4%-8.7%$1.19B$277.25M-22.00350Positive NewsOPKOPKO Health4.1315 of 5 stars$1.38-2.8%$2.75+99.3%-9.6%$1.10B$713.10M-5.522,997GERNGeron3.0099 of 5 stars$1.40-2.1%$4.19+199.1%-69.2%$893.22M$76.99M-10.77229Positive News Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives MannKind Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
